NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.
Myers ER, McCrory DC, Mills AA, et al. Effectiveness of Assisted Reproductive Technology. Rockville (MD): Agency for Healthcare Research and Quality (US); 2008 May. (Evidence Reports/Technology Assessments, No. 167.)
This publication is provided for historical reference only and the information may be out of date.
Question 2: Among women of reproductive age, what are the benefits and risks of Clomid® and Pergonal® (or other injectable super-ovulatory drugs), and Glucophage®, and how do they vary in different patient populations?
| Study | Study Design | Patients | Clinical Presentation | Results | Comments/Quality Scoring | |
|---|---|---|---|---|---|---|
| StudyID | Geographical location: [city & state (U.S.) or city & country (foreign)]
Study dates: [month & year] Size of population (no. of patients): [num/denom for screening studies] Number of cycles analyzed: Number of cycles per patient: [please calculate] Study type: RCT [exclude all other study designs] Interventions: [list] | Age: Mean (SD): Median: Range: Race/ethnicity (n [%]): Diagnoses (n [%]): Unexplained infertility: Endometriosis: Male factor: Tubal factor: PCOS: Other (specify): Inclusion criteria: Exclusion criteria: | Definition(s) of outcome(s): Pregnancy: Live birth: Multiples: Complications (specify): | [For each treatment, report outcomes with 95% CIs (if given) and p-values for differences. Abstract data only when outcomes are reported on a per-patient basis; otherwise EXCLUDE.]
1) [2×2 table for RR - List outcome here and replace “Exp +” and “Exp -” in far left column of 2×2 table with labels for interventions; if placebo included, enter this in bottom row of 2×2 table, under the active intervention. ] | [IF ARTICLE SHOULD BE EXCLUDED, PLEASE EXPLAIN WHY HERE]
[COMMENT ON BIASES, ETC. AFFECTING CLINICAL INTERPRETATION] Quality assessment: [+ if appropriate quality, - if not; add text as needed to describe] Randomization method: Blinding: Dropout rate < 20%: Adequacy of randomization concealment: This article is also relevant to: [delete as appropriate] Question 1b Question 1c Question 3 Question 4 | |
| 2) [2×2 table for RR - List outcome here and replace “Exp +” and “Exp -” in far left column of 2×2 table with labels for interventions; if placebo included, enter this in bottom row of 2×2 table, under the active intervention. ] | ||||||
| 3) [Free-text outcome]:
4) [Free-text outcome]: | ||||||
Question 3:Among women of reproductive age, which laboratory, clinical, and other practice approaches result in the highest successful singleton pregnancy (or live-born) rates, and what practices lead to high multiple rates?
| Study | Study Design | Patients | Clinical Presentation | Results | Comments/Quality Scoring | |
|---|---|---|---|---|---|---|
| StudyID | Geographical location: [city & state (U.S.) or city & country (foreign)]
Study dates: [month & year] Size of population (no. of patients): [num/denom for screening studies] Number of cycles analyzed: Number of cycles per patient: [please calculate] Study type:RCT [exclude all other study designs] Interventions: [list] | Age: Mean (SD): Median: Range: Race/ethnicity (n [%]): Diagnoses (n [%]): Unexplained infertility: Endometriosis: Male factor: Tubal factor: PCOS: Other (specify): Inclusion criteria: Exclusion criteria: | Definition(s) of outcome(s): Pregnancy: Live birth: Multiples: Complications (specify): | [For each treatment, report outcomes with 95% CIs (if given) and p-values for differences. Abstract data only when outcomes are reported on a per-patient basis; otherwise EXCLUDE.]
1) [2×2 table for RR - List outcome here and replace “Exp +” and “Exp -” in far left column of 2×2 table with labels for interventions; if placebo included, enter this in bottom row of 2×2 table, under the active intervention. ] | [IF ARTICLE SHOULD BE EXCLUDED, PLEASE EXPLAIN WHY HERE]
[COMMENT ON BIASES, ETC. AFFECTING CLINICAL INTERPRETATION] Quality assessment: [+ if appropriate quality, - if not; add text to describe] Randomization method: Blinding: Dropout rate < 20%: Adequacy of randomization concealment: This article is also relevant to: [delete as appropriate] Question 1b Question 1c Question 2 Question 4 | |
| 2) [2×2 table for RR - List outcome here and replace “Exp +” and “Exp -” in far left column of 2×2 table with labels for interventions; if placebo included, enter this in bottom row of 2×2 table, under the active intervention. ] | ||||||
| 3) [Free-text outcome]:
4) [Free-text outcome]: | ||||||
Question 4: What are the adverse outcomes of ovulatory drug-induced pregnancies and of pregnancies achieved with IVF? Is there evidence to link these adverse outcomes with the treatments and not the underlying maternal health or gestational age problems?
| Study | Study Design | Patients | Clinical Presentation | Results | Comments/Quality Scoring | |
|---|---|---|---|---|---|---|
| StudyID | Geographical location: [city & state (U.S.) or city & country (foreign)]
Study dates: [month & year] Size of population (no. of patients): [num/denom for screening studies] Number of cycles analyzed: Number of cycles per patient: [please calculate] Study type: [delete all that do not apply] RCT Cohort Case-control Other (specify) | Age: Mean (SD): Median: Range: Race/ethnicity (n [%]): Diagnoses (n [%]): Unexplained infertility: Endometriosis: Male factor: Tubal factor: PCOS: Other (specify): Inclusion criteria: Exclusion criteria: | Definition(s) of outcome(s): [Include:
| [Please calculate ORs (case-control) or RRs (RCT, cohort), as appropriate. If possible and appropriate, stratify results by age.]
1) [2×2 table - List outcome here and replace “Risk +” and “Risk -” in far left column of 2×2 table with labels for risk factors/interventions; if placebo included, enter this in lower row of 2×2 table, under the active intervention.] | [IF ARTICLE SHOULD BE EXCLUDED, PLEASE EXPLAIN WHY HERE]
[COMMENT ON BIASES, ETC. AFFECTING CLINICAL INTERPRETATION] Quality assessment: [+ if appropriate quality, - if not; add text to describe] For RCT: Randomization method: Blinding: Dropout rate < 20%: Adequacy of randomization concealment: For cohort study: Unbiased selection of the cohort (prospective recruitment of subjects): Large sample size: Adequate description of the cohort: Use of validated method for ascertaining exposure: Use of validated method for ascertaining clinical outcomes: Adequate follow-up period: Completeness of follow-up: Analysis (multivariate adjustments) and reporting of results: For case-control study: Valid ascertainment of cases: Unbiased selection of cases: Appropriateness of the control population: Comparability of cases and controls with respect to potential confounders: Appropriateness of statistical analyses: This article is also relevant to: [delete as appropriate] Question 1b Question 1c Question 2 Question 3 | |
| 2) [2×2 table - List outcome here and replace “Risk +” and “Risk -” in far left column of 2×2 table with labels for risk factors/interventions; if placebo included, enter this in lower row of 2×2 table, under the active intervention. ] | ||||||
| 3) [Free-text outcome]:
4) [Free-text outcome]: | ||||||
- Appendix C: Data Abstraction Forms (Questions 2–4) - Effectiveness of Assisted R...Appendix C: Data Abstraction Forms (Questions 2–4) - Effectiveness of Assisted Reproductive Technology
Your browsing activity is empty.
Activity recording is turned off.
See more...